LLY Stock Forecast: When Great Isn’t Cheap
Highlights
- GLP-1 leadership drives long-term growth
- Current valuation exceeds intrinsic value
- Sell recommendation due to limited upside
Overview
Eli Lilly and Company is a global pharmaceutical company focused on discovering, developing, and commercializing innovative medicines across diabetes, obesity, oncology, immunology, neuroscience, and cardiovascular disease. The company has established itself as a leader in metabolic disease through its blockbuster GLP-1 therapies, Mounjaro and Zepbound, which have driven exceptional revenue growth and significantly strengthened Lilly’s market position. Supported by substantial investments in research and development, manufacturing capacity, and a broad late-stage pipeline, Lilly is well positioned to capitalize on the growing global demand for innovative therapies.
From a valuation perspective, Lilly is viewed as a high-growth pharmaceutical company with strong earnings momentum, robust free cash flow generation, and a diversified pipeline that supports long-term growth. The company’s premium valuation reflects market expectations for continued expansion in the obesity and diabetes markets, although investors should also consider risks such as increasing competition, pricing pressure, regulatory changes, and the successful execution of its manufacturing expansion and product pipeline.
Financial Results
(Figure 1: LLY vs. Peers for profitability margins and debt structure.)
Compared with its peer group, Eli Lilly demonstrates superior profitability across all major operating metrics. The company reports an LTM gross margin of approximately 82%, exceeding the peer average of 74%, reflecting its strong pricing power and the favorable economics of its high-margin pharmaceutical portfolio. Lilly also outperforms peers in EBITDA margin (50% vs. 40%), EBIT margin (48% vs. 32%), and net income margin (35% vs. 17%), highlighting its ability to convert revenue into earnings more efficiently. These industry-leading margins are primarily driven by the rapid commercial success of its obesity and diabetes therapies, a favorable product mix, and disciplined cost management.
Lilly also employs a more leveraged capital structure than its peers, with total debt-to-capital of approximately 58% versus the peer average of 7%, and a total debt-to-EBITDA ratio of 1.2x compared with 0.3x for peers. While this indicates greater financial leverage, the debt level remains manageable given the company’s exceptional profitability, strong free cash flow generation, and robust earnings growth. Overall, Lilly’s financial profile reflects a company that combines industry-leading operating performance with prudent use of leverage to support strategic investments in manufacturing capacity and future growth initiatives.
(Figure 2: FY2021 to FY2025 LLY’s Capex-to-Revenue)
Lilly’s capital expenditure intensity has increased significantly over the past five years, with CAPEX as a percentage of revenue rising from 4.6% in 2021 to 12.0% in 2025. The sharp increase beginning in 2023 reflects the company’s aggressive investment in expanding manufacturing capacity, particularly for its blockbuster obesity and diabetes therapies, Mounjaro and Zepbound. These investments include new production facilities, supply chain expansion, and infrastructure upgrades aimed at meeting rapidly growing global demand and alleviating supply constraints.
The sustained upward trend demonstrates management’s commitment to supporting long-term growth rather than maximizing near-term free cash flow. While elevated capital expenditures may temporarily pressure cash flows and returns on invested capital, they are expected to strengthen Lilly’s competitive position by increasing production capacity, supporting future product launches, and enabling continued revenue growth. This investment strategy should be reflected in the valuation model through higher near-term CAPEX assumptions, followed by gradual normalization as major expansion projects are completed.
(Figure 3: FY2021 to FY2025 LLY’s Capex Growth)
Lilly’s capital expenditures have grown rapidly over the past four years, with CAPEX increasing 41.6% in 2022, 85.9% in 2023, 46.7% in 2024, and 55.0% in 2025. The sharp acceleration in 2023 marked the beginning of the company’s large-scale manufacturing expansion to support the surging demand for its blockbuster obesity and diabetes therapies, particularly Mounjaro and Zepbound. Although the growth rate moderated after 2023, CAPEX has remained elevated, indicating that Lilly continues to invest heavily in expanding production capacity and strengthening its global manufacturing network.
The consistently high level of capital spending reflects management’s long-term growth strategy rather than a temporary increase in investment. These expenditures are expected to alleviate supply constraints, support future product launches, and reinforce Lilly’s competitive position in the rapidly growing GLP-1 market. For valuation purposes, this trend justifies maintaining elevated CAPEX assumptions over the near-term forecast period before gradually normalizing as major expansion projects are completed.
(Figure 4: FY2021 to FY2025 LLY’s Debt-to-Equity Ratio)
Lilly’s debt-to-equity ratio has fluctuated over the past five years, declining from 184.9% in 2021 to 151.9% in 2022 before rising sharply to approximately 244% in both 2023 and 2024. The ratio then decreased to 165.3% in 2025, suggesting an improvement in the company’s capital structure. The increase in leverage during 2023 and 2024 coincided with Lilly’s significant investments in manufacturing capacity and infrastructure to support the rapid commercialization of its blockbuster GLP-1 therapies, while the subsequent decline reflects strong earnings growth and an expanding equity base.
Despite maintaining a relatively high debt-to-equity ratio, Lilly’s leverage does not indicate financial distress. The company continues to generate strong operating cash flows and industry-leading profitability, providing ample capacity to service its debt obligations. The moderation in leverage during 2025 suggests that earnings growth is beginning to outpace debt accumulation, supporting a healthier balance sheet while allowing the company to continue funding long-term strategic investments.
Future Business Outlook
Eli Lilly’s long-term growth outlook remains highly favorable, driven by sustained demand for its diabetes and obesity franchise and a robust pipeline of innovative therapies. The company is expected to benefit from continued adoption of Mounjaro and Zepbound, expanding insurance coverage, and international market penetration as obesity treatment becomes more widely accepted. To support this demand, Lilly has committed billions of dollars toward expanding its manufacturing capacity, which should alleviate supply constraints and enable continued revenue growth over the coming years. Beyond metabolic diseases, the company’s late-stage pipeline in oncology, immunology, neuroscience, and Alzheimer’s disease provides additional growth opportunities and helps diversify future revenue streams.
Despite its strong outlook, Lilly faces several risks that could influence its long-term performance. Competition from other pharmaceutical companies developing GLP-1 and next-generation obesity treatments may place pressure on market share and pricing, while regulatory scrutiny over drug pricing and reimbursement remains an ongoing concern. In addition, the company must successfully execute its manufacturing expansion and continue delivering positive clinical trial results to sustain investor expectations. Nevertheless, Lilly’s strong balance sheet, industry-leading profitability, and commitment to innovation position the company to remain one of the leading growth companies in the global pharmaceutical industry over the long term.
Stock Forecast: Discounted Cash Flow Model (DCF)
(Figure 5: Discounted Cash Flow Valuation Summary)
Using Eli Lilly’s historical financial data from FY2021 to FY2025, we developed a five-year forecast to estimate the company’s intrinsic value using a discounted cash flow (DCF) model. As Eli Lilly reports as a single operating segment, revenue projections were based on analyst consensus estimates for 2026 and 2027, followed by a historical arithmetic average growth rate of approximately 22% for the remaining forecast period. The model assumes continued strong demand for Lilly’s blockbuster GLP-1 therapies, Mounjaro and Zepbound, supported by expanding manufacturing capacity, broader global adoption, and increasing insurance coverage. Operating expenses, including cost of sales, research and development, and selling, general and administrative expenses, were forecast using historical averages as a percentage of revenue to maintain consistency with the company’s historical operating performance while reflecting continued investment in innovation and commercialization.
The pro forma model assumes Lilly will continue investing aggressively in manufacturing expansion to support long-term growth. Capital expenditure assumptions were based on historical averages as a percentage of revenue, representing investments across land, buildings, equipment, and construction in progress to expand production capacity for its rapidly growing diabetes and obesity franchises. Depreciation was estimated using the straight-line method with useful lives consistent with historical accounting policies. The model also incorporates a 4.07% long-term debt interest rate, a 2% annual increase in long-term debt, and a 1% annual debt repayment assumption. Working capital items were forecast using historical averages, while maintaining relatively stable operating efficiency throughout the forecast period. A 4.0% terminal growth rate was applied to reflect Lilly’s long-term growth potential, supported by its robust product pipeline and continued innovation, while remaining consistent with long-term economic growth expectations.
Based on these assumptions, the DCF model produced an implied enterprise value of approximately $933.6 billion and an equity value of approximately $890.2 billion, corresponding to an intrinsic value of approximately $998 per share. Compared with Eli Lilly’s market price of $1,206.50 as of June 25, 2026, the valuation suggests that the shares are trading above their intrinsic value, resulting in a Sell recommendation. Although Eli Lilly remains one of the highest-quality pharmaceutical companies globally, supported by industry-leading profitability, strong cash flow generation, and a dominant position in the rapidly expanding obesity and diabetes markets, the current market valuation appears to reflect highly optimistic growth expectations. Consequently, we believe investors have limited upside at current prices despite the company’s excellent long-term business fundamentals and attractive product pipeline.
Stock Forecast: Multiples Valuation
(Figure 6: LLY Multiples Valuation Summary)
The multiple-based valuation was performed using forecasted FY2026 financial metrics and the current average trading multiples of comparable pharmaceutical companies. Applying the peer average NTM P/E multiple of 15.47x, NTM EV/EBITDA multiple of 13.13x, and NTM EV/Revenue multiple of 5.00x results in implied values of $494, $655, and $430 per share, respectively. The EV/EBITDA approach produces the highest valuation, reflecting Lilly’s exceptional profitability and strong cash flow generation, while the revenue multiple generates the lowest estimate, suggesting that the market assigns a significant premium to Lilly’s earnings quality rather than revenue growth alone.
Compared with Lilly’s current trading multiples of 32.96x NTM P/E, 25.14x NTM EV/EBITDA, and 13.02x NTM EV/Revenue, the company trades at a substantial premium to its peer group across all valuation metrics. This premium reflects investors’ expectations for sustained leadership in the obesity and diabetes markets, continued commercialization of its GLP-1 portfolio, and strong long-term earnings growth. However, the implied values from all three multiple-based approaches remain well below the current market price, suggesting that much of Lilly’s future growth potential has already been priced into the stock and supporting a Sell recommendation from a relative valuation perspective.
(Figure 7: LLY Multiples Comparison with Peers)
The comparable company analysis further illustrates the premium valuation currently assigned to Eli Lilly relative to its large-cap pharmaceutical peers. Lilly trades at 13.0x NTM EV/Revenue, 25.1x NTM EV/EBITDA, and 33.0x NTM P/E, substantially above the peer averages of 5.0x, 13.1x, and 15.5x, respectively. The premium is supported by Lilly’s industry-leading growth profile, driven by the commercial success of its GLP-1 therapies, Mounjaro and Zepbound, as well as its strong pipeline and superior profitability. In contrast, peers such as Bristol-Myers Squibb, Pfizer, AbbVie, Johnson & Johnson, and AstraZeneca generally exhibit slower expected earnings growth and more mature product portfolios.
Although Lilly’s premium valuation is justified by its stronger growth prospects and higher operating margins, the magnitude of the valuation gap suggests that investors have already priced in a significant portion of its future earnings potential. Any slowdown in demand, manufacturing execution challenges, increased competition in the obesity market, or pricing pressure could result in multiple compression. Consequently, while Lilly remains one of the highest-quality pharmaceutical companies in the sector, its current trading multiples appear demanding relative to peers, supporting a more cautious valuation outlook.
Stock Forecast: Analysts’ Consensus
(Figure 8: Analyst Recommendations for LLY as of 6/30/2026)
Based on the analyst consensus from Bloomberg, market sentiment toward Eli Lilly remains overwhelmingly positive despite its premium valuation. As of June 30, 2026, 29 of 36 analysts (80.6%) maintain Buy recommendations, while 6 analysts (16.7%) rate the stock as Hold, and only 1 analyst (2.8%) recommends Sell. The consensus 12-month target price is $1,238, representing a modest 2.3% upside from the current share price of $1,212. Recent research from major investment banks, including Morgan Stanley, Jefferies, Barclays, and BMO Capital Markets, continues to assign favorable ratings such as Overweight, Buy, and Outperform, reflecting confidence in Lilly’s long-term growth prospects.
While analyst sentiment remains highly optimistic, the relatively limited upside implied by the consensus target price suggests that much of Lilly’s future growth has already been priced into the stock. Investors continue to value the company’s leadership in the obesity and diabetes markets, robust product pipeline, and strong earnings outlook. However, our DCF and comparable company valuation analyses indicate that the current market price exceeds the company’s intrinsic value under reasonable assumptions. Consequently, although we remain positive on Lilly’s long-term business fundamentals, we maintain a Sell recommendation based on valuation, as the current share price appears to reflect exceptionally optimistic growth expectations.
Conclusion
Eli Lilly remains one of the highest-quality pharmaceutical companies globally, supported by its leadership in the rapidly expanding obesity and diabetes markets, industry-leading profitability, and a strong pipeline of innovative therapies. Continued investments in manufacturing capacity, research and development, and commercialization position the company for sustained long-term growth, while its strong cash flow generation and operating efficiency reinforce its competitive advantage within the pharmaceutical industry.
Despite these attractive fundamentals, both our discounted cash flow (DCF) and comparable company valuation indicate that Lilly’s current share price reflects highly optimistic growth expectations. The DCF model estimates an intrinsic value of approximately $998 per share, while the multiple-based valuation produces an implied value range of $430 to $655 per share, all below the current market price. Although analyst sentiment remains overwhelmingly positive, we believe the company’s premium valuation leaves limited upside and increases the risk of multiple compression should growth expectations moderate. Therefore, we assign a Sell recommendation based on valuation rather than business quality, as the current market price appears to exceed the company’s intrinsic value under reasonable long-term assumptions.
It is worth paying attention that the stock-picking AI of I Know First has a high signal on the one-year market trend forecasts. The light green for the short-term forecasts is mildly bullish, while the darker green is a strong bullish signal for all forecast horizones.
To subscribe today click here.
Please note-for trading decisions use the most recent forecast.
